Solventless Coating for Medical Electrical Leads
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Pacemaker leads face challenges with increased stimulation threshold due to electrode-body tissue interaction and difficulty in designing a lead body with fluoropacity for visualization, as current solutions either prevent substantial reduction in lead body diameter or inadequately address physiological processes involved in healing response and visualization.
Innovation Solution
A solventless method for forming a therapeutic agent eluting coating on medical electrical leads, involving dispensing a suspension of therapeutic agents in an uncured silicone medical adhesive onto the lead body, followed by curing to create a polymer matrix layer, and optionally incorporating fluoro-opaque materials like tungsten or platinum particles to enhance visualization.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a drug collar or plug containing therapeutic agent is incorporated into the lead body, then the stimulation threshold is reduced, but the overall lead body diameter cannot be substantially reduced
Solution Approach 1:
The patent combines the therapeutic agent delivery function and the fluoroscopic visualization function into a single integrated coating layer applied directly to the lead body surface. This eliminates the need for separate drug collars or plugs, thereby maintaining the therapeutic effect while reducing the overall lead body diameter.
Solution Approach 2:
The coating layer serves multiple functions simultaneously: it delivers therapeutic agents (anti-inflammatory, anti-proliferative), provides fluoroscopic opacity for visualization, and protects the lead body surface. This multi-functionality allows reduction of lead diameter by consolidating multiple components into one.
2Difficulty of detecting and measuring
If a radiopaque ring is placed on the lead body for visualization, then fluoropacity is achieved, but the lead body diameter cannot be substantially reduced
Solution Approach 1:
The patent merges the fluoroscopic visualization function with the therapeutic agent delivery function in a single coating layer. Fluoro-opaque materials (tungsten, platinum, barium sulfate particles) are incorporated into the same coating matrix that contains therapeutic agents, eliminating the need for separate radiopaque rings.
Solution Approach 2:
The fluoroscopic opacity is localized to the coating layer applied only at specific segments of the lead body where visualization is needed, rather than requiring a full circumferential radiopaque ring. This allows visualization functionality with minimal impact on lead diameter.
3Quantity of substance
If a large drug collar is used to deliver therapeutic agent, then effective drug delivery is achieved, but the lead body diameter is increased
Solution Approach 1:
The patent uses a thin film coating layer applied directly to the lead body surface to deliver therapeutic agents. This thin-film approach provides effective drug delivery through controlled release mechanisms while maintaining a minimal thickness that does not substantially increase the lead body diameter.
Solution Approach 2:
The patent extracts the therapeutic agent delivery function from the bulk lead structure and places it in a separate, thin coating layer. This allows the lead body to maintain its original diameter while the coating layer provides the necessary drug delivery capability.
4Ease of manufacture
If solvent-based coating methods are used, then coating application is simplified, but solvent-related degradation occurs
Solution Approach 1:
The patent changes the key parameter of the coating formulation from solvent-based to solvent-free. This parameter change eliminates solvent-related degradation and instability issues while maintaining the ability to apply the coating uniformly to the lead body surface through controlled dispensing and curing processes.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method reduces the stimulation threshold by controlled release of therapeutic agents and provides fluoropacity for improved visualization during and after implantation, minimizing lead body diameter and ensuring a predictable drug release profile without solvent-related degradation.
Implementation Method 1
curing the suspension to form a polymer matrix layer that is free of residual solvent
Data Source
AI summary
A solventless method for forming a coating on a medical electrical lead is described. The method includes combining particles of a therapeutic agent with a polymeric material in a flowable form in the absence of a solvent to form a uniform suspension. A predetermined amount of the suspension is dispensed onto a portion of the lead and is then cured to form the therapeutic agent eluting layer. Additional layers such as a primer layer, fluoro-opaque layer and/or a topcoat layer can be formed using the solventless method. Employing a solventless method may avoid contraction of the layer being formed due to solvent evaporation during the curing process, and may facilitate greater control over the thickness of the therapeutic agent eluting coating.